About EBSA11 Conference - Florence
EBSA11 Conference - Florence
Programme
Thursday, 3 April 2008 |
|
Opening and introduction | 09.00 - 09.30 |
Session 1a: Current and future issues in high containment (BSL3 & BSL4) | 09.30 - 10.30 |
Chair: Anton de Paiva, Imperial College London, United Kingdom | |
What went wrong and lessons learned at Pirbright Heather Sheeley, Health Protection Agency, United Kingdom; Uwe Mueller-Doblies, Instiute for Animal Health, United Kingdom |
09.30 - 09.50 |
The Italian experience in facing emerging and re-emerging infectious diseases: the National Institute for Infectious Diseases "Lazzaro Spallanzani" |
09.50 - 10.10 |
Biosafety-Europe: What did we achieve and what could be recommended to the EU ? Kathrin Summermatter, Institut für Viruskrankheiten und Immunprophylaxe, Switzerland |
10.10 - 10.30 |
Coffee break |
10.30 - 11.00 |
Seession 1b: Issues in high containment | 11.00 - 11.20 |
Chair: Anton de Paiva, Imperial College London, United Kingdom | |
Post polio eradication biosafety |
11.00 - 11.20 |
Session 2: Chris Collins Lecture | 11.20 - 12.05 |
Chair: Anton de Paiva, Imperial College London, United Kingdom | |
Emerging Zoonosis Malcom Bennett, Liverpool University, United Kingdom |
11.20 - 12.05 |
Lunch |
12.05 - 13.00 |
Session 3: Animal biosafety | 13.00 - 14.00 |
Chair: Massenzio Fornasier, Siena Biotech, Italy | |
Occupational health issues Martin Kuster, Novartis International AG, Switzerland |
13.00 - 13.20 |
Facility considerations |
13.20 - 13.40 |
Animals in containment Steve Lever, Defence Science & Technology Laboratory, United Kingdom |
13.40 - 14.00 |
Session 4: Break outs | 14.00 - 15.15 |
A. Biosafety Europe: Quo vadis? Moderator: Jürgen Mertsching, Medinzinische Hochschule, Germany This project concentrated on high containment facilities across Europe. Information was gathered from different European countries, from various expert groups and stakeholders. The responses showed a lack of harmonization on biosecurity regulations, biosafety standards with regard to classification, nomenclature and safety measures. In view of these findings, is there a need for harmonization and to what extent? What are the benefits of harmonization? High containment facilities are expensive to construct and maintain. Sufficient funding must be available to enable high standards for biosafety and biosecurity measures. Who defines the right safety level and where is the right cost - risk reduction balance? How can we ensure that a facility is safe and still cost-effective? Training of those involved in high containment activities is a key element of good biosafety/biosecurity management. How could a training programme best meet the demands of these facilities? What long term goal(s) could the biosafety community strive for? Participants are invited to join the breakout session to share with the Biosafety Europe Project members their views and ideas on the project's topics. |
14.00 - 15.15 |
B. Molecular tools for the surveillance of mandatory biosafety requirements |
14.00 - 15.15 |
C. Laboratory registers of GMOs/pathogens/biological materials: what is good practice? This break out session will debate the levels of knowledge required at the national, institutional and research group level of work involving biological agents being undertaken in European institutions. For example, is it reasonable and practical for every institution to be able to report on all current holdings and activities within their organisations? Is it feasible to achieve this when dealing with biological agents that are in themselves capable of replication from minute quantities. The difficulties associated with maintaining accurate registers is weighed against the ever increasing global concerns over biosecurity, and hence, on expectations that Governments, Institutions and individual groups know what skeletons they hide in the freezer. |
14.00 - 15.15 |
D. Validation of laboratory disinfection procedures This session will examine quality assurance issues in laboratory disinfection. How do you know that a particular disinfectant is performing effectively in the situation in which you are using it? How much can you rely on manufacturer's or published data? If you need to verify your particular procedures, how do you go about it? |
14.00 - 15.15 |
E. Training of facility support personnel by BSP Moderator: Gary Burns, AstraZeneca, United Kingdom; Asa Szekely-Björndal, Swedish Institute for Infectious Disease Control, Sweden This break-out session is intended to provide a forum to consider training requirements for support and maintenance personnel in connection with activities involving biohazards. The approach will be to identify the various types of worker and roles associated with the activities and to examine associated tasks. Training requirements and provision will be considered in the context of protecting personnel from infection, preventing dissemination within the facility and avoiding release to the environment. |
14.00 - 15.15 |
F. EC Biopreparedness Green paper - next steps Through the Green Paper launched by the European Commission (EC) during 2007, the EC intended to stimulate a debate and launch a process of consultation at European level on how to reduce biological risks, and to enhance preparedness and response ("bio-preparedness"). After analysis of the results of this consultation, the EC is interested in discussing the next steps with the biosafety community. This session offers you the opportunity to discuss with a member from the EC proposed changes to enhance biosafety, laboratory biosecurity and bio-preparedness and present your opinions. |
14.00 - 15.15 |
Session 5: Posters and coffee break | 15.15 - 16.15 |
Session 6: Facility Engineering and decontamination | 16.15 - 17.15 |
Chair: Gary Burns, AstraZeneca, United Kingdom | |
Engineering for biosafety - air changes and distribution Philippe Stroot, Xibios Biosafety Consulting, Belgium |
16.15 - 16.35 |
Decontamination validation of BSL3 agents in industrial facilities |
16.35 - 16.55 |
Study of plasmochemical method to inactivate microorganisms of different groups |
16.55 - 17.15 |
AGM |
17.30 |
Conference dinner |
20.00 - 23.30 |
Friday, 4 April 2008 |
|
Session 7: Biosecurity | 09.00 - 10.30 |
Chair: Asa Szekely-Björndal, Swedish Institute for Infectious Disease Control, Sweden | |
BIOSAFE Project - dual use Jackie Duggan, Health Protection Agency, United Kingdom |
09.00 - 09.20 |
Synthetic biology: A perilous goldmine? Peter Clevestig, SIPRI Institute, Sweden |
09.20 - 09.40 |
University of Cambridge biosecurity practices |
09.40 - 10.10 |
Biosafety and biosecurity and the biological weapons convention |
10.10 - 10.30 |
Coffee break |
10.30 - 11.00 |
Session 8: Risk assessment | 11.00 - 12.00 |
Chair: Patrick Rüdelsheim, Perseus, Belgium | |
Emerging and reemerging diseases from a Russian central European perspective Yuliya Ananyina, Gamalei Institute of Epidemiology and Microbiology, Russia |
11.00 . 11.20 |
Bio-nanotechnology Martin Kuster, Novartis International AG, Switzerland |
11.20 - 11.40 |
New lines of on-going research on designing means of diagnostics of infectious disease in SRCAMB |
11.40 - 12.00 |
Lunch |
12.00 - 13.30 |
Session 9: Report on break outs | 13.30 - 14.00 |
Session 10: Biorisk management | 14.00 - 15.00 |
Chair: Luca Nelli, Siena Biotech, Italy | |
Safety and security management at a research institute - sharing the best practices from the biological, nuclear and chemical fields Goedele De Bruyne , Biosafety Coordinator, European Commission - Joint Research Centre - Institute for Reference Materials and Measurements, Belgium; Pierre Kockerols , Head of the Health, Safety, Environment and Security sector, Euro-pean Commission - Joint Research Centre - Institute for Reference Materials and Measurements, Belgium |
14.00 - 14.20 |
Laboratory biorisk management standard in practice Pierre Mathot, GlaxoSmithKline Biologicals, Belgium |
14.20 - 14.40 |
Anthrax and African Drums. An investigation into the source of a fatal case of human anthrax Allan Bennett , Nigel Silman, Graham Lloyd and the HPA CEPR Bioresponse Team Novel and Dangerous Pathogens HPA Centre For Emergency Preparedness and Response, United Kingdom |
14.40 - 15.00 |
Closing remarks EBSA President 2008 - 2009 |
15.00 |